Viking Therapeutics Reports New Data from VK2735 Obesity …
5 天之前 · Mild nausea was reported in 23 (32%) VK2735-treated subjects compared with 11% among placebo subjects. No moderate or severe nausea was reported. Vomiting was reported in three (4%) VK2735-treated subjects. Diarrhea was reported in five subjects (7%) receiving VK2735 compared with four subjects (21%) receiving placebo.
Viking Therapeutics' Reveals Early-Stage From Experimental Oral …
4 天之前 · Reductions in body weight were progressive throughout the study, with no plateau observed for weight loss at 13 weeks. In addition, up to 88% of patients in VK2735 treatment groups achieved ≥10% ...
Viking Therapeutics to Highlight Clinical Data from VK2735 …
2024年10月28日 · News provided by Viking Therapeutics, Inc. ... Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented ...
News & Events - Viking Therapeutics InvestorRoom
2024年2月27日 · Data from a Phase 1 and a Phase 2a trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. The company is also evaluating an oral formulation of VK2735 in a Phase 1 trial.
Viking Therapeutics Announces Results from Phase 1 Clinical Trial …
2024年3月26日 · Oral VK2735 demonstrated encouraging safety and tolerability following 28 days of once-daily dosing. Among subjects receiving VK2735, all treatment emergent adverse events (TEAEs) reported to...
Viking Therapeutics Announces Positive Top-Line Results from …
2024年2月27日 · Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Viking Therapeutics' Early Clinical Data Continue to Build Case for …
5 天之前 · In a small Phase 1 study, Viking’s once-daily oral VK2735 led to dose-dependent reductions in weight with greatest weight loss — an average 6.8% at 28 days — achieved in the highest of the ...
Viking Therapeutics Stock Climbs On Positive Data From VK2735 …
4 天之前 · The company added that persistent weight loss effects were observed at follow-up visits through Day 57, ranging up to 8.3 percent from baseline, four weeks after the last dose of VK2735 was ...
Viking Therapeutics' weight-loss pill shows 'great outcome' in trial
4 天之前 · The news sent the stock sharply higher in premarket trade, before it surrendered those gains to trade down 7% as investors locked in some of its recent gains. ... The study of VK2735 among obese ...
Viking Therapeutics Reports New Data from VK2735 Obesity …
4 天之前 · Poster Presentation #017: First-in-Human Study of an Oral Formulation of the GLP-1/GIP Co-Agonist VK2735 in Healthy Adults. Poster #017 presented updated data from the previously reported 28-day ...